Randomized Phase II Trial of Docetaxel plus Nivolumab or Docetaxel alone in patients with advanced non-squamous NSCLC and previous clinical benefit on treatment with single agent Nivolumab HCRN LUN15-233



Study Overview

The purpose of this study is to determine if using nivolumab and docetaxel together is better at controlling lung cancer than using docetaxel by itself.


Study Description

The purpose of this study is to determine if using nivolumab and docetaxel together is better at controlling lung cancer than using docetaxel by itself.

Additional Information:

Participants will not be paid for their participation.



Research Study Identifier: TX7329
ClinicalTrials.gov Identifier: NCT1610963813 (LUN15-233)
Principal Investigator: Greg Durm, MD


Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.